Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Moxian Inc. (MOXC) Offers a One-Stop-Shop for Businesses to Engage with Consumers

Developed in Shenzhen, China, Moxian provides a social marketing and promotional platform for businesses. The company’s platform, called MO-Promo, uses the concepts of social media and online gaming to promote businesses. This includes a Social Customer Relationship Management System (SRM), MO-Points, online gaming, a social networking site called MO-Zone, and a Social Loyalty program that rewards users for using their MO-Points. Moxian clients can use the SCRM system to stay ahead of consumer trends while advertising and campaigning their businesses on the website.

MO-Promo works out of the Weibo site, the company’s social media platform. This is where consumers can access blogs, podcasts, shopping, news, and more all while connecting to a social network. Topics on the site include history, education, movies, health, art, fashion, beauty, and even jokes.

Consumer users can then play a variety of online games such as Texas Poker, Destiny Tower, and Yulong Pass. During each game, users earn points which can be redeemed at the Points Mall. Prizes, which are sponsored by both Moxian and its clients, include more games, a Microsoft Surface 2, prepaid cards, Starbucks mugs, umbrellas, and more.

Fortunately, the fun doesn’t have to stay on a desktop. The company has also developed the Moxian+ app for both Android and Apple phones. Here, users can continue to network while being kept aware of local events and activities. They can also play games and redeem their winnings through the versatile app.

The combination of social media and online play gives companies the opportunity to advertise to the masses. Both consumers and businesses alike can network and learn from each other in a single place. Moxian encourages users to revisit the site by offering incentives, like points and prizes, which leads to a recurring marketable audience.

For more information, visit the company’s website at

Posted in Moxian Inc. MOXC | Leave a comment

Oakridge Global Energy Solutions, Inc. (OGES) Targeting Key Niche Market Segments with Innovative Battery Systems

Oakridge Global Energy Solutions is an integrated energy storage solutions company that uses state-of-the-art technology in the design, development and manufacture of high-quality cells, batteries and energy storage systems. The company is committed to ushering in a brand new era in battery manufacturing, and a quick look at its core values highlights the commitments that help Oakridge differentiate itself from the competition in the stored energy marketplace.

An unrelenting dedication to corporate pride and commercial success forms the foundation of the Oakridge business model, and a commitment to innovation has allowed the company to develop a diverse, ‘Made in the U.S.A.’ product line that addresses four high-demand target markets – including motive applications, stationary living space power, remote control and portable devices, and starter motor batteries. In October, Oakridge expanded on this formula by announcing the production release of its Pro Series product line of heavy duty battery systems for task-oriented vehicles.

“This is a very exciting product line and we are really pleased with the way that it underscores our mission statement of on-shoring jobs and manufacturing back to the U.S.A. by providing the market with another Made in the U.S.A. product instead of having to rely on imported products,” Steve Barber, executive chairman and chief executive officer of Oakridge, stated in a news release.

The company’s focus on bringing manufacturing jobs back to the U.S. has caught the attention of local lawmakers and entrepreneurs. Last month, Oakridge was recognized by Florida Governor Rick Scott following the launch of its new corporate headquarters and manufacturing center in Palm Bay. The expansion, which is part of Oakridge’s existing and ongoing $270 million investment in its lithium-ion battery development and manufacturing facilities in Brevard County, Florida, is expected to create approximately 1,000 new jobs in the community.

According to a study by Research and Markets, the global lithium-ion battery market is expected to grow at a CAGR of 14.4 percent over the next four years, reaching $33.1 billion by 2019. While much of this growth is expected to occur in the automotive sector, global sales of lithium-ion powered energy storage systems are also expected to increase from less than $2 billion in 2015 to roughly $6 billion by 2020.

By providing high-quality products that address a number of viable markets, Oakridge is in a strong position to capitalize on this market growth in the years to come. Look for the company to build upon the early success of its current product line as it continues to target key niche market segments with its lithium-ion battery products in the future.

For more information, visit

Posted in Oakridge Global Energy Solutions Inc. OGES | Leave a comment

Craft Brew Alliance (BREW) Has Exciting Plans for 2016

Headquartered in Portland, Oregon, and founded in 1981, Craft Brew Alliance has grouped together three of the oldest and most well-respected craft brewers from Oregon, Washington and Hawaii to form a company with the resources and industry know-how needed to succeed in the ultra competitive adult beverage space.

Redhook Ale Brewery, founded in Seattle in 1981, is Washington’s largest craft brewery;  Widmer Brothers Brewing, founded in 1984, takes the same title in Oregon. Kona Brewing Company, founded a decade later, is Hawaii’s oldest and largest craft brewery. BREW also reaches out to the health-conscious beer drinker with its Ommission brand, the first craft beer in the U.S. focused exclusively on brewing craft beer with traditional ingredients – including malted barley – which is gluten free. The last brew in the company’s current lineup is Square Mile Cider, a tribute to early American settlers who purchased the first plots of land in the Pacific Northwest.

BREW operates five breweries and five pub restaurants across the U.S., and earlier this year earned the “Craft Beer Company of the Year” award from Hooters of America. Another significant milestone for BREW was its partnership with Anheuser-Busch InBev (NYSE: BUD) to utilize the “King of Beer’s” behemoth national distribution network.

Building on its strength in national chains and continuing to activate distinctive retail promotions, and continuing to nurture its significant partnership with Anheuser-Busch InBev, BREW has a clearly defined growth strategy for the new year.

In 2016, BREW plans on building out its Emerging Business division and expanding with new strategic partners that increase its relevance in key beer geographies while leveraging the company’s national footprint. The plan is already starting to unfurl, as the company’s two recent partners, Appalachian Mountain Brewery and Cisco Brewers, have added North Carolina and Massachusetts to its home markets.

BREW will continue to build on its strategic partnerships with Appalachian Mountain Brewery and Cisco Brewers through alternating proprietorships and master distribution agreements that will enable both growing breweries to meet increasing demand in their respective core markets of North Carolina and the northeast.

Redhook Brewery, which celebrates its 35th anniversary in 2016, will continue to focus on its legacy position as the “Granddaddy of Craft” in its home state of Washington. Redhook unveiled classic new packaging for its flagship beers Longhammer IPA and ESB, as well as soon-to-be-released American Pale Ale, which will launch nationally, and ESL, extra special lager, which will launch in Washington. Redhook also announced a new seasonal line-up: Blackhook, Summerhook and Winterhook, which will launch nationally and carry the bold packaging design. Redhook will soon be announcing the location for its new brewpub in Seattle, a move that brings the iconic brand back to its roots.

Widmer Brothers Brewing will continue building on the momentum achieved through the brand’s renewed focus on Hefe, which remains Oregon’s favorite craft beer. Widmer Brothers also revealed that it would begin offering Hefe in cans, initially in Oregon, to celebrate the beer’s 30th anniversary in 2016 and meet the increased demand for its iconic American-style wheat in a more portable package. The brand also teased a new dark beer, Steel Bridge Porter, to launch in 6-packs and draft in Oregon and Washington. The new porter will round out a core line-up that includes Hefe, Upheaval IPA, Replay IPA and Drop Top Amber.

Now a Top 10 national craft beer brand, Kona Brewing Co. will bring its unique brand of “Liquid Aloha” to life through a new television campaign, as well as a pint, bottle or can of Kona Brewing flagships Longboard Lager and Big Wave Island Ale. In 2016, Kona will bring back its popular Aloha Series, which includes Koko Brown, Lemongrass Luau and Pipeline Porter nationally. Additionally, Kona’s Wailua Wheat will return to California. In Hawaii, Kona will launch its iconic Lavaman Red in package for the first time and continue its Makana Series, which connects Kona Brewing with local charities that support Hawaii’s sustainability and pristine environment.

Omission Beer will continue to capitalize on the growing trend among consumers to avoid gluten. The brand will invest in growing awareness and distribution for its category leading flagships, Omission Pale Ale and Omission Lager. Additionally, the brand will continue working with corporate partners such as Wanderlust, a health and wellness event series, to bring the great taste of Omission to consumers looking to live a healthier lifestyle.

BREW will also continue to partner with the Chive’s Resignation Brewery and its 30+ million monthly online visitors to grow KCCO’s (Keep Calm and Chive On) Gold Lager, with an emphasis on its home market of Texas and the military.

Square Mile, which has grown to be the No. 2 hard cider brand in the Pacific Northwest and a Top 10 craft cider brand, will expand distribution in its existing core markets in the west with the brand’s Original and hopped-version Spur & Vine.

Financially, BREW’s growing market saturation appears to be paying off. In 2014, the company reported net sales of $200 million and net income of $3.1 million, an increase of 12 percent and 55 percent, respectfully, over the previous year’s results. Analysts predict BREW will report net sales of $211 million in 2015,  and if the company’s aggressive growth strategy is any implication is that it will easily deepen its roots in the $19.6 billion U.S. craft beer market.

For more information visit

Posted in Small Cap News | Leave a comment

Synta Pharmaceuticals (SNTA) Using Teamwork to Battle Cancer

Founded in 2000, Lexington, Massachusetts-based Synta Pharmaceuticals focuses on the development of its oncology medicines. The company’s main product ganetespib, is an Hsp90 inhibitor used in the treatment of lung cancer, breast cancer, acute myeloid leukemia, myelodysplastic syndrome, ovarian cancer, and refractory sarcoma. Hsp90 Drug Conjugate is the company’s proprietary, small molecule cancer drug development program. The company has several drugs in phase 2 and phase 3 clinical trials, as well as some just starting out in the phase 1 stage.

When developing pharmaceuticals, it is vital to have a team of experts helping navigate the highly complicated and very involved waters of the development process. To this accord, Synta Pharmaceuticals recently announced the formation of its Expert Oncology Panel:

David E. Avigan, M.D. – chief section of Hematological Malignancies and Bone Marrow Transplantation, Beth Israel Deaconess Medical Center associate professor, Medicine, Harvard Medical School

Bruce Allan Chabner, M.D. – director of Clinical Research, Cancer Center Massachusetts General Hospital Cancer Center

Jeffrey A. Engelman, M.D., Ph.D. – director, Center for Thoracic Cancers Massachusetts General Hospital Cancer Center, associate professor of Medicine Harvard Medical School

F. Stephen Hodi, Jr., M.D. – director, Melanoma Center Director, Center for Immuno-Oncology, associate professor of Medicine Harvard Medical School, Dana Farber Cancer Institute

Martin J. Murphy, D. MedSc, Ph.D., FASCO – chairman and chief executive officer AlphaMed Consulting, Inc.

Neil Lee Spector, M.D. – associate professor of Medicine, Sandra Coates associate professor, associate professor of Pharmacology & Cancer Biology, member of the Duke Cancer Institute

Cancer costs the world more money than any other disease, according to the American Institute of Cancer Research (AICR), racking up annual costs of $895 billion. More than half a million Americans die of cancer every year, making the disease the second-leading cause of death in the United States. Comparatively, heart disease costs $753 billion while traffic accidents and diabetes each cost about $204 billion.

Statistics like these drive companies like Synta Pharmaceuticals to aggressively usher their products to market and race toward eliminating the disease. By building a panel consisting of world-renown doctors and experts in the oncology field, Synta Pharmaceuticals has already taken a progressive step in the process of getting a new potentially life-saving drug into the hands of cancer patients.

Stay tuned as we follow the company’s progress along, as it is cashed up and recently cut staff back to 33 employees in order to maintain operations until at least the middle of 2017.

For more information, visit


Posted in Small Cap News | Leave a comment

International Stem Cell Corp. (ISCO) Injection of Ethically-Derived Neural Stem Cells for the Treatment of Parkinson’s to Be Tested in Australia

The true forefront in medicine today is a broad offensive where medical and research professionals are now pulling out all the stops in a never-ending war against broad-spectrum degenerative diseases like cancer or degenerative diseases of specific tissues, such as Parkinson’s and Alzheimer’s, which severely cripple a patient’s central nervous system (CNS). Unfortunately, there is very little in the way of truly therapeutic options for patients with degenerative CNS diseases.

In the case of Parkinson’s, dopamine-generating neurons in the midbrain (substantia nigra) progressively die off, resulting in a variety of motor control issues (dyskinesia) at first, with dementia, insomnia, and severe depression or emotional problems typically following in later stages. There is no currently known cure for Parkinson’s and the standard of care consists primarily of medications designed to manage and/or provide relief from the symptoms.

The main family of drugs used to offset Parkinson’s symptoms is Levodopa (L DOPA, which metabolizes into dopamine), but MAOIs (monoamine oxidase inhibitors) and dopamine agonists have seen a significant increase of use in recent years as a first choice, in order to prolong the start of L DOPA treatment. For you see, prolonged use of L DOPA typically results in dyskinesia that is equivalent to the long-term effects of Parkinson’s itself.

Because less than 10 percent of L-DOPA actually makes it through the blood-brain barrier, the vast majority of it is metabolized elsewhere in the body, resulting in numerous side effects like nausea and joint stiffness, in addition to the aforementioned Parkinson’s-like motor control problems. MAOIs, historically already in wide usage as a treatment for atypical depression, are pretty effective at delimiting the primary monoamine oxidase that degrades dopamine, MAO-B, and thus are able to somewhat offset the lack of dopamine that is being caused by neuronal loss.

As you can see, the only solutions for Parkinson’s patients which are currently available aren’t really solutions at all, and carry with them the looming inevitability of a lost battle against this degenerative disease. A truly disheartening reality for patients and their families. Long-term options for Parkinson’s patients and their families are severely limited as well and include invasive surgery, or palliative care designed merely to improve quality for end of life patients. Reasonable extrapolations from official Parkinson’s Disease Foundation data indicates that the number of people on earth currently suffering from the disease is likely close to, or over 10 million. Some 60,000 or more people in the U.S. alone are diagnosed with Parkinson’s each year, meaning the real number is likely much higher, after factoring in all the cases that go undiagnosed, and unreported.

Hence the undisputable potential value of the proprietary, scalable and ethical human parthenogenetic (asexual reproduction from unfertilized egg) stem cell (hpSC) technology currently being developed by International Stem Cell Corp. (OTCQB: ISCO). Because hpSCs are self-renewing multipotent cells, they represent an as-yet essentially untapped goldmine of therapeutic developments which could provide solutions for countless degenerative diseases, and do so across multiple tissue types. The company’s hpSC platform for chemically stimulating eggs to reproduce, which uses a series of different activation techniques in order to create sizeable batches of healthy adult cells that are HLA/immune-matched (human leukocyte antigen) either to the individual or to the general population, has led to an exciting novel therapeutic cellular product consisting of human parthenogenetic neural stem cells (hPNSCs).

Because hPNSCs have been shown to be able to actually differentiate into dopaminergic neurons, therapy using these injected cells represents a wholly-new approach to the problem of Parkinson’s, wherein the root cause of the disease is addressed directly. Moreover, transplanted hPNSCs have been shown to express powerful brain-protecting neurotrophic factors in pre-clinical animal model studies, meaning that not only does this product hold the potential to simply grow new dopamine-producing cells, it can also help shield the remaining healthy cells from degeneration and/or death. ISCO’s recent announcement that the company is now moving full steam ahead towards phase I/IIa human clinical trials in Australia, subsequent to a meeting with the Australian Therapeutics Goods Administration and signage of an LOI with the conducting facility, Royal Melbourne Hospital, is a major milestone for the company. A milestone that puts ISCO squarely in the pole position for developing the first true Parkinson’s therapy.

TGA approval for the phase I/IIa clinical trials is expected sometime this month, with enrollment commencing shortly after, and ISCO could have a real winner on its hands depending on whether the results jog with those generated by the preceding nine-month safety GLP study of 300 rodents, which showed zero tumor growth in any of the subjects receiving transplanted cells. ISCO seems to have overcome the two major stumbling blocks that have hindered other developers in this field: immune-related tissue rejection and tumor formation.

The chemically close-to-nature methodology whereby the company generates its hpSCs is likely a main reason its therapies have had such preclinical successes, and one need look no further than the results for the other candidates (such as those for metabolic liver and degenerative eye diseases) in ISCO’s therapeutic pipeline in order to get a good idea of where the Parkinson’s therapy is headed. A savvy observer will note that the probability of success for ISCO with its hPNSC phase I/IIa clinical trials is telegraphed readily by the demonstrated versatility of the platform in allowing for a robust pipeline of several promising indications. The hpSC platform looks solid and ISCO could have one or two disruptive commercial breakthroughs on its hands in the near future.

Unlike many preclinical biopharma developers, ISCO has a cash pipeline already in place to help fund the expensive work of drug trials, with two wholly-owned subsidiaries that benefit from the company’s hpSC platform: Lifeline Cell Technology and Lifeline Skin Care. Respectively engaged in the sale of human cell culture products/reagents, as well as cosmeceuticals based on a proprietary extract derived from hpSCs, these two profitable subsidiaries not only help feed the R&D machine that is ISCO, they represent promising long-term opportunities in and of themselves. Quarterly financial data out as of November 16 from ISCO shows that Lifeline Cell Technology sales were up handsomely in Q3 (ended September 30), climbing 22 percent compared to the same quarter last year, alongside a nine percent jump in the company’s total consolidated revenue over the same period. Having wound down its multiple preclinical studies during the first six months of 2015, ISCO has managed to slash its cash burn rate and the company is now eager to see the fruits of its labor emerge from human clinical trials of hPNSCs in Parkinson’s.

The ability to grow functional, immune-matched adult human stem cells without the need to fertilize an egg is as ground-breaking a revolution in medicine as it sounds. And ISCO is basically the tip of the spear here too, alongside a tiny handful of other companies, many of whom lack the crucial IP and pre-clinical success story to deliver on a platform solution that could eventually hit hard and fast across the gamut of degenerative and similar diseases.

To find out what the buzz is all about, visit

Posted in International Stem Cell Corp. ISCO | Leave a comment

OurPet’s Company (OPCO) Offers Two Platforms for Twice the Fun

Being a top dog in the pet industry means more scalability to reach a wider customer base. That’s why OurPet’s Company (OTCQX: OPCO) gives two brand options to its niche customers. The OurPets brand focuses on specialty customers while the Pet Zone Brand centers on food/drug/mass-market channels. Each has its own website where pet owners can get the latest products in safety, health, waste management, and fun.

OurPet’s designs, produces, and markets a variety of innovative, high quality accessory and consumable pet products in the United States and overseas. It began with the Big Dog Feeder product that improves posture and comfort for canines. Most of their award-winning products are patented and boast being the only ones of their kind on the market. Cat owners can get their own consumable Kitty Cat Grass to grow at home or the EZ Scoop Litter Box with Odor Control Spray. Felines can also frolic with the Hide and Go Squeak Interactive Toy. Dogs can have the Buster Food Cube and the WonderBowl for their eating needs. The company’s products aim at bringing out a pet’s natural instincts for a healthier lifestyle.

In 2006, OurPet’s purchased all of the assets of its chief competitor, Pet Zone. The company now has a platform for its own products while integrating those of Pet Zone in another. Pet Zone products and accessories aim at improving the health, vitality, and safety of pets. Its goal is to offer high-end products at affordable rates. Feline friends can purchase the Mini Food-N-Fountain Deluxe or the Purr-Ivacy Place Pop-Up Litter Box Canopy along with many scratchers and toys. Dog owners can buy the Cozy Cottage Dog House, treat dispensers, and other food bowl accessories.

The pet industry has grown from $17 billion in 1994 to $74.23 billion in 2014. That number is expected to increase to $77.03 billion this year alone. During this time, OurPet’s has grown 3-5 times faster than the overall industry and has no plans of slowing down. The company gives investors the opportunity to participate in this expanding market while offering consumers the chance at buying multiple products through multiple brands.

For more information, visit the company’s website at

Posted in OurPet’s Company OPCO | Leave a comment

Fuling Global, Inc. (FORK) Primed to Grow in Global Plastic Serviceware Market Following Completion of Initial Public Offering

Over the past 20 years, Fuling Global has grown from a small manufacturer of plastic household articles and baskets into one of China’s largest exporters of disposable serviceware. Today, the company operates precision manufacturing facilities in both the United States and China that specialize in the production of a wide variety of plastic serviceware products – including disposable cutlery, drinking straws, cups and plates. Fuling’s products are primarily sold to customers throughout the U.S. and Europe and include some of the world’s most recognizable brands, such as Wendy’s (NASDAQ: WEN), Burger King (NYSE: QSR), KFC (NYSE: YUM), Walmart (NYSE: WMT) and McKesson (NYSE: MCK).

According to market research firm The Freedonia Group, the U.S. foodservice disposables industry, of which Fuling is a part, accounted for roughly $18 billion in 2014, and steady growth is expected to continue in the years to come. By 2019, the report estimates that the industry will grow to $21.9 billion, spurred by rising demand in both the retail and hospitality segments. In order to better capitalize on this growth, Fuling completed an initial public offering of its ordinary shares and commenced trading on the NASDAQ Capital Market on November 4, 2015.

“Our IPO on NASDAQ is an important step toward becoming a significant player in the global plastic serviceware market,” Guilan Jiang, chairwoman of Fuling, stated in a news release. “We expect the increased publicity and name recognition that come with being a NASDAQ-listed company, combined with our access to new sources for capital, position us well for growth.”

Following its IPO, Fuling is in a strong position to build on its recent financial performance. In the third quarter of 2015, the company leveraged a significant drop in raw material costs in order to achieve a 17 percent year-over-year increase in net income. In European markets, Fuling recorded revenues in excess of $2 million for the period, an increase of 45 percent over the previous year. As it continues to focus on increasing its penetration in pivotal global markets and expanding its production capacity, Fuling will look to promote sustainable growth moving forward.

“We are encouraged by this quarter’s results, which show improved gross and operating margins, net income and sales volume,” stated Xinfu Hu, chief executive officer of Fuling.

With a roster of multinational customers and an expanding product line, Fuling is in a favorable position to increase its market share in the global disposable serviceware market. Look for the company to lean on the marketability of its IP portfolio – including nearly 30 patents focused on environmentally-friendly materials and technology – in order to fulfill its vision of becoming an international leader in the production of disposable cutlery, straws and other serviceware.

For more information, visit

Posted in Small Cap News | Leave a comment

ContentChecked Holdings, Inc. (CNCK) Gains Wide Exposure in ValuePenguin Publication

ContentChecked Holding today issued a press release announcing that one of its degreed nutritionists, Tara Zamani, provided valuable insight in a recent ValuePenguin article on employment as a dietician/nutritionist.

“Los Angeles is full of food gurus, raw foodies, vegans, vegetarians and nutrition-savvy individuals. I love working in L.A. as a nutritionist because many of my clients already have a good understanding of nutrition and are very open-minded when it comes to holistic health. L.A. is a hub for holistic nutrition, alternative medicine and many people here prefer to use natural remedies for healing, rather than traditional methods,” Zamani stated in the article. “Nutritionists are in demand, which makes it a great city for a new nutritionist to start a career. L.A. also offers many healthy restaurants, farmers’ markets, co-ops, health food stores and wellness centers, and guiding clients to choose healthier eating places is easy.”

ValuePenguin currently has an audience of approximately 350,000 monthly viewers, and the article published ( links back to ContentChecked’s website where readers can learn more about the company’s offerings.

Contributing nutritional expertise is an important part of ContentChecked’s efforts to raise awareness of its family of health apps and help Americans better manage their food allergies, migraines and overall health.

“Each ContentChecked employee is highly valued for their strong contributions and hard work that firmly roots our company in the marketplace,” says Kris Finstad, CEO of ContentChecked, the developer of MigraineChecked, SugarChecked and ContentChecked, a family of health apps for people with dietary restrictions and/or food preferences. “It’s always a pleasure to see the expertise of one of our team members being sought after and published in a well-recognized and read publication like ValuePenguin.”

For more information on the company, visit

Posted in ContentChecked Holdings Inc. CNCK | Leave a comment

Moxian, Inc. (MOXC) Creative & Marketing VP Edmund Ooi Interviews with MissionIR

MissionIR today announced the online availability of its interview with Mr. Edmund Ooi, Vice President and Director of Creative & Marketing for Moxian, Inc. (OTCQB: MOXC). The full audio interview is available at

Moxian is a social multi-media company building an application platform and merchant rewards system that enable small- and medium-sized businesses to better engage their customers and enhancing their marketing initiatives.

After providing a brief overview of the company, Mr. Ooi describes his own experience creating national marketing projects in Singapore, China, the Middle East and Los Angeles, which he currently applies in helping Moxian create product improvements and applications to a larger audience.

He then offers considerable information on other key members of the company’s management team and how their previous endeavors in international markets contribute to Moxian’s growth. Together, this roster of executives has positioned the company to achieve several milestones in 2015, including rapid market acceptance and strategic personnel additions.

“I think we have seen a great leap in our skillset and our ability to [offer] much stronger and more robust software,” Mr. Ooi says.

Moving forward, Mr. Ooi explains Moxian’s near and longer-term outlook, which includes expanding its merchant base; increasing advertising, transaction and sponsorships revenues; uplisting the company’s common stock; and increasing shareholder value.

Mr. Ooi concludes the interview with a recap of recent company news, including an $8.9 million private placement to facilitate Moxian’s continued corporate growth.

Posted in Moxian Inc. MOXC | Leave a comment

Moxian, Inc. (MOXC) Targeting Expansive Chinese Social Media Market with Moxian+ Social Commerce Platform

Unlike the United States, China currently boasts several social networks with more than 100 million active users. These platforms serve a collection of different purposes ranging from messaging and video sharing to blogging and ecommerce, and this diversity of usage creates an opportunity for new entrants with a unique commerce or communications offering to gain market share despite the existence of established competitors.

In 2014, the China Internet Network Information Center reported that there were roughly 618 million internet users throughout the Asian nation, representing a penetration rate of approximately 46 percent. Among these internet users, over 90 percent have a social media account. For comparison, just 67 percent of U.S. internet users engage in social media. However, the opportunity in China extends beyond the ability to reach a large target audience. According to the Data Center of China Internet, 38 percent of users claim they are more likely to buy items recommended by other social media users.

Moxian, Inc. is attempting to capitalize on these favorable market conditions by developing an innovative social commerce platform targeting the expansive Chinese market. Moxian+ will allow retailers and consumers to trade, communicate and locate goods and services while simultaneously being guided through the use of sophisticated, data-driven marketing techniques. Moxian plans to deploy its commerce platform in major metropolitan areas of China, Singapore and Malaysia by the end of the year.

Following its official launch, the Moxian+ platform is expected to be a comprehensive tool targeting the specific needs of brick-and-mortar businesses with internet and mobile-enabled business intelligence. While the platform will primarily connect and promote interaction of businesses and consumers online, it will also promote improved interaction across a full range of traditional sales channels.

Moxian+ is expected to serve as a sustainable source of revenue for Moxian, as the company will utilize advertising and membership fees in exchange for its services. While the majority of merchants are expected to subscribe to a basic program with a flat monthly fee, the platform will also be capable of addressing more complex requirements in exchange for additional fees commensurate with the value-added benefits.

For prospective shareholders, Moxian’s efforts to break into the expansive social networking and ecommerce markets of China could foreshadow an opportunity for the company to promote strong financial growth for the foreseeable future. Look for Moxian to continue progressing toward the official launch of Moxian+ in the weeks to come.

For more information, visit

Posted in Moxian Inc. MOXC | Leave a comment